Bayer’s 103% Rally Exacts a Technical Toll: Overbought Signals Test Investor Conviction After Supreme Court Win and Ruveon Launch

Bayer shares double in value after Supreme Court ruling and Ruveon LLC spin-off. Overbought RSI signals caution despite settlement progress and pharma pipeline strength.

The transformation of Bayer’s stock from perennial DAX laggard to this year’s comeback story has been nothing short of dramatic. Two catalysts — a pivotal Supreme Court ruling and the structural separation of its troubled US glyphosate business — have collectively reshaped investor sentiment. The shares closed Thursday at €53.04, brushing against a new 52-week high of €53.38, and have more than doubled over the past twelve months with a gain of roughly 103%.

That headline figure, however, masks a more complex picture. The rally accelerated sharply in recent weeks: the stock surged 8.25% on Thursday alone to hit an intraday high of €52.72, and over the past 30 days it has rocketed nearly 54% higher. Year-to-date the advance stands at approximately 40%. The pace of the move has pushed technical indicators deep into overbought territory, raising questions about how much further the run can extend before a pullback.

A structural solution for a legal albatross

The strategic pivot that ignited the re-rating centres on the creation of Ruveon LLC, a newly formed subsidiary headquartered in St. Louis. Ruveon will assume control of Bayer’s US operations for glyphosate-based products, with Alfonso Alba Ordonez at the helm. The carve-out is part of an ongoing five-year restructuring programme within the agriculture division. For now, Bayer retains full ownership of Ruveon, but the move is widely interpreted as a preparatory step towards a future partial sale or complete spin-off that would isolate the litigation exposure from the parent company.

The legal backdrop has brightened considerably. The US Supreme Court dealt a significant blow to thousands of pending claims by ruling that federal labelling requirements from the Environmental Protection Agency pre-empt more stringent state-level cancer warnings. That decision has opened the door to a comprehensive settlement. A preliminary agreement worth US$7.25 billion is already on the table, and Bayer has set aside provisions in the double-digit billions. The final approval hearing is scheduled for 19 August 2026.

Operative strength returns to the spotlight

With the worst of the legal uncertainty now quantifiable, investors have refocused on Bayer’s underlying business. The pharmaceuticals segment is gaining momentum, driven by growth assets such as Kerendia and Nubeqa. Another potential catalyst lies with the US Food and Drug Administration, which is currently reviewing the stroke therapy candidate Asundexian. The company’s ability to advance its pipeline underscores a narrative that extends beyond courtroom drama.

Deutsche Bank was quick to adjust its view. Analyst Virginie Boucher-Ferte upgraded the stock from Hold to Buy and lifted the price target from €45 to €60, citing the gradual dissipation of litigation overhang and a clearer path to operational visibility.

The price of momentum

Yet the breakneck pace of the rally has come at a cost. The Relative Strength Index has climbed to an extreme 85.1 points, signalling that the market is heavily overbought. Annualised volatility stands at 63.32%, reflecting elevated nervousness among traders. Profit-taking would come as little surprise in the near term.

Fundamental headwinds also remain. Bayer’s high debt burden continues to weigh, and the pharmaceuticals division will need to sustain its recent performance to offset declining revenues elsewhere. The company’s market capitalisation has recovered to €46.17 billion, a far cry from the lows of the past two years but still well below historical peaks.

The next major test for the new-look investment case arrives on 4 August 2026, when management publishes second-quarter results. By then, the market will also have a clearer view on whether the settlement receives final judicial blessing. For now, Bayer’s turnaround has captured the imagination of the market — but the technical warning signs suggest that the easiest gains may already have been taken.